All News

GSK's blockbuster diabetes drug Avandia was the subject of a number of studies this week offering good and bad news. But the company's big challenge is going to be FDA's advisory review panel set to meet in two short weeks.

Emerging Pharma Leaders 2010

FDA's meeting on the adoption of REMS for certain prescription opioids doesn't begin until July 22, but the agency's proposal released Tuesday portends a meeting fraught with conflict over the balance between curbing abuse and protecting patient access.

Pfizer was forced (voluntarily) to put the kibosh on a fast-tracked Wyeth drug after some not-so-favorable postmarket data. Was this a good catch or an endemic problem with expedited drugs?

A new study indicates that doctors are no longer switching offices - largely due to current economic woes. What does this mean for sales reps? Pharm Exec interviews SK&A to find out more about its survey.

Mark Gordon looks at how real partnership opportunities are developing in a virtual pharma world.

Merck has established a stable of 15 to 20 investigators focused solely on cancer compounds in an effort to boost efficiency and help move along the bevy of oncology products the firm has in its pipeline.

A heavily rigid agency network structure that fights against their strategic objectives is the last thing clients should be looking for.

The trend is strong, bold ideas that travel across cultures.

An ideal partner is one that will work with manufacturers on a variable cost basis, providing the ability to scale resources up and down as new products are introduced and marketing and sales needs change.

To assume that growing a marketing presence in emerging markets automatically requires a global agency network is a flawed assumption.

Sure, there might be a few key audiences whose view of your reputation is critical, but targeting them is fairly simple and often inexpensive. More times than not, it's better to keep your head down than raise the banner and lead the field.

Independence equals creativity, and solutions

Strategy-listening, seeing, thinking-all need to be done locally.

The monolithic dictates out of marketing and agency headquarters in New York and London-and the way they are forced on local marketing efforts-work to undermine adoption at the local level

In China people view expenditures on pharmaceuticals as a "cost" rather than a "purchase"

The pharma industry has only recently seen the kinds of price pressures that the retail industry has operated under for decades.

The companies with the best corporate reputations have responsibility initiatives that earn their way, but very few of them started in response to a perceived problem or a bit of bad press.

Emerging Pharma Leaders

The public-interest charity takes on pharma-influenced medicing and drug-resistant bacteria.

Pharma companies can maximize partnership benefits with social media.

Innovation in industry has always required a strong internal champion; the danger is a process led by the risk-adverse and externally-driven stakeholder consensus called "death by faint praise." Is this really what we mean by "bold partnerships?"

May 24, 2010.

In the wake of megamergers and healthcare reform, Pfizer and Merck both produce fairly positive first quarter results

One Pill Makes You Better?

Cash-rich Big Pharmas are hedging their bets to cover both segments under the rubric of "diversification." If it sticks to the wall, then buy it.

Marketers must focus on getting busy women the help they need in making critical decisions about their healthcare.

A new Cegedim Dendrite study shows just how ill-equipped pharmaceutical companies are to deal with spending disclosure legislation, and how many are turning to third parties to do the job.